Physician profile
Kyle Edwin Johnson
NPI 1730307570
$68,746.16
in general payments reported to CMS, 2019-2025
18 companies · $187 in 2025
The $187 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $25K · 2021: $27K · 2024: $137 · 2025: $187.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $324.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $43,849.93 | 2019-2021 | |
| Abbvie INC. | $23,603.74 | 2021 | |
| Janssen Pharmaceuticals, INC | $213.07 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $125.92 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $121.68 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $120.60 | 2024 | Prolaris |
| Sunovion Pharmaceuticals INC. | $97.28 | 2019 | |
| Urogen Pharma, INC. | $94.22 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $92.76 | 2019-2020 | |
| Alkermes, INC. | $92.36 | 2019-2025 | Aristada, Lybalvi |
| Vanda Pharmaceuticals INC. | $70.34 | 2019-2020 | |
| Lundbeck LLC | $61.75 | 2019 | |
| Merck Sharp & Dohme LLC | $47.45 | 2019 | |
| Sun Pharmaceutical Industries INC. | $46.57 | 2025 | |
| Avanir Pharmaceuticals, INC. | $37.10 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $35.87 | 2019 | |
| Neuronetics, INC. | $23.60 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11.92 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.